Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

11 treatments under study, led by Cct Long Covid

Research Leaders

12 sponsors active, led by Azienda Socio Sanitaria Territoriale di Lecco

Related Conditions

Often studied with 20 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 10 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

10%

1 trials in Phase 3/4

Results Transparency

0%

0 of 6 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

8Total
Not Applicable (3)
Phase 1 (1)
Phase 1/2 (1)
Phase 2 (2)
Phase 3 (1)

Trial Status

Completed6
Unknown3
Withdrawn1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 6 completed trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT05747534Phase 2Completed

AT1001 for the Treatment of Long COVID

NCT05524532Phase 3CompletedPrimary

Effects of Immulina TM Supplements With PASC Patients

NCT05539950Not ApplicableWithdrawnPrimary

Cardiopulmonary Rehabilitation in Post-acute COVID-19 Syndrome

NCT05638620Phase 1CompletedPrimary

Dual Sympathetic Blocks for Patients Experiencing Sympathetically-Mediated Symptoms From Long COVID

NCT05736939CompletedPrimary

Gender Differences in the Recovery Rate Following PR in Patients With Long COVID-19

NCT05815693Not ApplicableUnknownPrimary

Cognitive-behavioral Therapy for Mental Disorder in COVID-19 Survivors

NCT05812209Completed

Stellate Ganglion Block to Treat Long COVID 19 Case Series

NCT05582603Phase 1/2Unknown

Safety and Dosage of a Computerized Cognitive Training Program for Cognitive Dysfunction After COVID-19

NCT05483829Not ApplicableCompletedPrimary

Digital Health Intervention Based on Artificial Intelligence to Support the Personalized Recovery of Long COVID Patients Affected by Fatigue (AIDA)

NCT04949386Phase 2UnknownPrimary

Safety, Tolerability and Efficacy of S-1226 in Post-COVID-19 Subjects With Persistent Respiratory Symptoms.

Showing all 10 trials

Research Network

Common Treatments

  • Cct Long Covid1
  • Larazotide Acetate1
  • S1226 81
  • Immulina Tm1
  • Stellate Ganglion Block1

Active Sponsors

  • Azienda Socio Sanitaria Territoriale di Lecco1
  • Massachusetts General Hospital1
  • Jonathann Kuo, MD1
  • Adhera Health, Inc.1
  • University of Mississippi Medical Center1

Top Investigators

Related Conditions

  • Long Covid4
  • Long Covid193
  • Post Acute Sequelae Of Covid192
  • Postacute Covid192
  • Dysautonomia2

Activity Timeline